Accelerating Innovation in Precision Medicine
Precision medicine has the potential to transform how we treat or even cure cancer. However, inefficiencies continue to slow the advancement of this breakthrough treatment approach. Challenges of this magnitude cannot be solved through scientific endeavors alone; they require novel business solutions.
Created by the Harvard Business School (HBS) Kraft Precision Medicine Accelerator, The Accelerating Innovation in Precision Medicine executive program strives to address this problem by convening leaders from the scientific, medical, technological, and business communities to explore business models in precision medicine and work together to accelerate progress in this burgeoning area.
Led by HBS faculty at the forefront of this emerging area, the program presents new methods for engaging patients in their care, expanding access to critical data, improving clinical trials, and targeting investments that can fuel scientific treatment breakthroughs.